Updated on 13 November 2013
The Xuri W25 builds on the GE Healthcare’s Wave bioreactor technology, which is widely used in the development and manufacture of biopharmaceuticals globally.
Mr Eric Roman, GM of research and applied markets, GE Healthcare Life Sciences, commented that, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable and efficient progress of cell therapies from clinical development to commercialization.”